National vaccine preparedness against pandemic influenza

Description

The Norwegian Institute of Public Health has carried out an open tender contest for the procurement of vaccine preparedness against pandemic influenza on behalf of the Ministry of Health and Care Services. The objective of the procurement was to ensure that Norway's residents have access to vaccines in the event of an influenza pandemic occurring during the contract period. The procurement was carried out as an open tender contest in accordance with the Public Procurement Act Parts 1 and 3. The procurement was carried out as an open tender competition. A contract was awarded for one lot for the delivery of 5 525 306 doses of vaccine. Lot 1: National vaccine preparedness against pandemic influenza - 5 525 306 doses. The Norwegian Institute of Public Health has carried out an open tender contest for the procurement of vaccine preparedness against pandemic influenza on behalf of the Ministry of Health and Care Services. The objective of the procurement was to ensure that Norway's residents have access to vaccines in the event of an influenza pandemic occurring during the contract period. Based on a population of 5 525 306 people (Statistics Norway's estimate for Norway's population in 2026), and that a two-dose regimen may be necessary to ensure full immunity in the entire population, the total number of vaccine doses against pandemic influenza is 11 050 612 doses. In accordance with the Call for Tender's section 1.4, approximately 3.9 million doses were already covered through the European Health Emergency Preparedness and Response Authority (HERA) at the time of the publication of the Call for Tender. The remaining needs were consequently 7 101 946 doses. The Norwegian Institute of Public Health intention was to enter into agreements with two suppliers. To ensure the best possible security of supply, a limit of 50% of the total need of 11 050 612 doses was decided for a single supplier. This means that a supplier who already has a contract for the delivery of a vaccine against pandemic influenza to Norway, can only be assigned a limited number of doses to ensure that this supplier does not exceed the limit of 50% of the total need. The 7 101 946 vaccine doses will be divided between two contracts. One contract includes the delivery of 5 525 306 doses (50%) and the other of 1 576 640 doses, which is the remaining number of doses needed to achieve 100% coverage of the total need. Each supplier can only be awarded one contract. Tenderers were allowed to present a set of prices (preparedness fee and price per vaccine) for each volume. It was not mandatory to offer prices for both volumes. A tenderer could, for example, choose to submit tenders for only one volume. A tenderer who was already awarded a contract for the delivery of vaccine doses against pandemic influenza to Norway was only allowed to submit tenders for the delivery of 1 576 640 doses against the contract. The Norwegian Institute of Public Health will award a contract for the reservation of 5 525 306 vaccine doses to the tenderer who presented the best price-quality ratio for this volume. (Supplier no. 1.) A contract of 1 576 640 vaccine doses should then be awarded to one of the remaining suppliers who had given the best price-quality ratio for this volume (Supplier no. 2). The contracts have an option for delivering a vaccine against pandemic influenza in the contract period. The number of doses that the Norwegian Institute of Public Health will order under each volume will depend on the chosen immunization regimen and the expected severity of the pandemic. The quality criterion was divided in to sub-criterias: Pharmaceutical quality (50%) Delivery (50%) Lot 2: National vaccine preparedness against pandemic influenza - 1 576 640 doses. The Norwegian Institute of Public Health has carried out an open tender contest for the procurement of vaccine preparedness against pandemic influenza on behalf of the Ministry of Health and Care Services. The objective of the procurement was to ensure that Norway's residents have access to vaccines in the event of an influenza pandemic occurring during the contract period. Based on a population of 5 525 306 people (Statistics Norway's estimate for Norway's population in 2026), and that a two-dose regimen may be necessary to ensure full immunity in the entire population, the total number of vaccine doses against pandemic influenza is 11 050 612 doses. In accordance with the Call for Tender's section 1.4, approximately 3.9 million doses were already covered through the European Health Emergency Preparedness and Response Authority (HERA) at the time of the publication of the Call for Tender. The remaining needs were consequently 7 101 946 doses. The Norwegian Institute of Public Health intention was to enter into agreements with two suppliers. To ensure the best possible security of supply, a limit of 50% of the total need of 11 050 612 doses was decided for a single supplier. This means that a supplier who already has a contract for the delivery of a vaccine against pandemic influenza to Norway, can only be assigned a limited number of doses to ensure that this supplier does not exceed the limit of 50% of the total need. The 7 101 946 vaccine doses will be divided between two contracts. One contract includes the delivery of 5 525 306 doses (50%) and the other of 1 576 640 doses, which is the remaining number of doses needed to achieve 100% coverage of the total need. Each supplier can only be awarded one contract. Tenderers were allowed to present a set of prices (preparedness fee and price per vaccine) for each volume. It was not mandatory to offer prices for both volumes. A tenderer could, for example, choose to submit tenders for only one volume. A tenderer who was already awarded a contract for the delivery of vaccine doses against pandemic influenza to Norway was only allowed to submit tenders for the delivery of 1 576 640 doses against the contract. The Norwegian Institute of Public Health will award a contract for the reservation of 5 525 306 vaccine doses to the tenderer who presented the best price-quality ratio for this volume. (Supplier no. 1.) A contract of 1 576 640 vaccine doses should then be awarded to one of the remaining suppliers who had given the best price-quality ratio for this volume (Supplier no. 2). The contracts have an option for delivering a vaccine against pandemic influenza in the contract period. The number of doses that the Norwegian Institute of Public Health will order under each volume will depend on the chosen immunization regimen and the expected severity of the pandemic. The quality criterion was divided in to sub-criterias: Pharmaceutical quality (50%) Delivery (50%)